AC
ALLR

Armistice Capital’s Allarity Therapeutics ALLR Stock Holding History

Armistice Capital’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-435
Closed -$195K – 301
2023
Q3 		$195K Buy
+435
New +$557K ﹤0.01% 203

Other funds holding ALLR

TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Armistice Capital's ALLR Position: Q4 2023 in Review

Armistice Capital sold out of Allarity Therapeutics (ALLR) in Q4 2023, closing a stake of 435 shares — an estimated $195K sold.

Armistice Capital first reported a position in ALLR in Q3 2023 and held it in 1 quarter. The position peaked at $195K in Q3 2023. 3 funds tracked by Wall St. Rank hold ALLR as of Q4 2023.

  • Armistice Capital reported no remaining Allarity Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Armistice Capital sold 435 Allarity Therapeutics shares in Q4 2023, an estimated $195K.
  • Armistice Capital first reported a position in Allarity Therapeutics in Q3 2023 and held it in 1 quarter.
  • Armistice Capital's Allarity Therapeutics position peaked at $195K in Q3 2023.
  • 3 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q4 2023.

Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.